Microba reports revenue growth, reduced losses in FY25

Microba Life Sciences Limited reported a 29.6% increase in revenues from ordinary activities, reaching $15,669,089 for the year ended June 30, 2025, while significantly reducing its loss attributable to owners by 25.1% to $(14,939,471). This improvement was driven by a streamlined focus on core diagnostic offerings, MetaXplore and MetaPanel, which saw accelerated adoption in both Australian and UK markets. Cash and equivalents stood at $11,740,910, bolstered by a successful capital raise of $14.5 million, with $8.45 million received in August 2025.

The company's strategy involved discontinuing legacy products and transitioning therapeutic programs from R&D to capital-light partnering, resulting in a reduction of research and development expenditure to $2,008,294. Operational highlights included a 136% growth in MetaXplore test sales in Australia, with 11,065 tests sold in FY25, and the successful launch of MetaXplore in the UK market.

Post-reporting period, on August 13, 2025, Microba completed a Tranche 2 placement and a share purchase plan, issuing 71,711,093 and 22,222,168 new ordinary shares, respectively, at $0.09 per share, raising an additional $6.45 million and $2.0 million respectively (before costs). These transactions further strengthened the group's cash position, reinforcing its ability to fund future growth and achieve regional break-even objectives for FY26.